Ashley Yeo is attached to the medtech titles within Informa’s Pharma intelligence division.
As Health Care editor on In Vivo (monthly hardcopy and online daily services), he writes and commissions news and feature material to meet the strategic business and market access information needs of senior players and device makers as they move innovations into the global medtech market place.
As part of the Principal Analyst team, he also contributes news delivery and insight needs across the group’s other medtech titles in the field of market access (global regulatory, reimbursement, policy changes). Key areas of focus are Germany, the UK and global themes, and EU and other outside global regulatory insight.
A linguist by training, he joined what was later to become Informa in mid-1988 as a French and German news reporter (with some other European languages also in the mix), and has been editor of three of the group’s titles (including Clinica) over a 14-year-period.
These duties are combined with supporting the growing Ask The Analyst service. He says: “This helps us as a group keep a close relationship with long-term and potential subscribers in a sector where insight and knowledge are key to our clients’ commercial success.”
Latest From Ashley Yeo
The national regulator is to undergo a review in 2021 as the UK begins life as a former EU member, presenting opportunities to be seized.
RSNA is the next major global medtech event to be run under a virtual format this fall. Under COVID-19, the major medtechs are finding different ways to demonstrate value, as Royal Philips explains.
The RSNA is the next global medtech exhibition and conference event to be run under a virtual format this fall.
COVID-19 put a dampener on Conmed’s 50th anniversary of operations, but CFO Todd Garner says the company is poised to resume its growth strategy, post-pandemic.
COVID-19 has accelerated the adoption of telehealth, but lasting change will only happen once digital health is institutionalized in health system work flows, says Teladoc Health’s Joe DeVivo.
Enthusiasm over German industry’s role in the coronavirus vaccine breakthrough should not detract from the focus on the national testing strategy, say the COVID-19 PCR testing labs.